Cell Response and Regulation (CRR)

细胞反应与调节 (CRR)

• 批准号: 10152544
• 负责人: Trudy Gale Oliver
• 金额: $ 6.62万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-05-09 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10152544
• 关键词: Address; American Cancer Society; Area; Award; Back; Basic Science; Cancer Biology; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Model; Cause of Death; Cell Cycle Stage; Cell Death; Cell Fate Control; Cell Proliferation; Cells; Cellular biology; Clinic; Clinical; Collaborations; Department of Defense; Development; Diagnostic; Disease; Disseminated Malignant Neoplasm; Distant; Doctor of Philosophy; Drosophila genus; Drug Targeting; Education; Effectiveness; Embryo; Environment; Fostering; Foundations; Funding; Genetically Engineered Mouse; Goals; Grant; Human; Infrastructure; Institutes; Investigation; Investigational Therapies; Journals; Malignant Neoplasms; Mediating; Metastatic to; Mission; Modeling; Neoplasm Metastasis; Organoids; Paper; Pathway interactions; Patients; Peer Review; Peer Review Grants; Population; Population Sciences; Pre-Clinical Model; Prevention; Principal Investigator; Publications; Publishing; Regulation; Research; Research Personnel; Resistance; Resource Sharing; Safety; Schools; Science; Scientist; Signal Pathway; Signal Transduction; Signaling Molecule; Site; Solid Neoplasm; Strategic Planning; Sushi Domain; System; Testing; Training; Translating; United States National Institutes of Health; Universities; Utah; Work; Xenopus; Zebrafish; biomarker development; cancer cell; cancer prevention; cancer therapy; cell motility; college; insight; interdisciplinary collaboration; investigator-initiated trial; malignant state; member; mouse model; neoplastic cell; next generation; novel; novel strategies; novel therapeutics; patient derived xenograft model; patient oriented research; prognostic; programs; response; self-renewal; stem; stem cells; success; therapy development; therapy resistant; translational pipeline; tumor; tumorigenesis

CELL RESPONSE AND REGULATION PROGRAM ABSTRACT The Cell Response and Regulation (CRR) Program is a basic science program at Huntsman Cancer Institute (HCI). CRR discovery science supports the Center’s mission “to understand cancer from its beginnings” by gaining new insight into basic mechanisms of cancer biology and providing a foundation for addressing critical clinical issues according to HCI’s strategic plan. CRR members use scientific ingenuity and the extensive Shared Resources provided by HCI to make new discoveries, and they collaborate with members of the Cancer Control and Population Sciences Program and the Experimental Therapeutics Program to translate these discoveries to the clinic and population in the areas of cancer prevention, target identification, biomarker development, prognostics, diagnostics, and treatment development. CRR research is centered on the following Specific Aims: 1) to elucidate mechanisms underlying cell proliferation, differentiation, and survival; 2) to uncover mechanisms and pathways mediating tumor metastasis; and 3) to understand tumor development and response to therapy. CRR is comprised of 37 members, representing 15 academic departments and four schools/colleges at the University of Utah. CRR members are well-funded, with $8.2M in peer-reviewed grant funding, of which $3.0M (33%) is from the NCI. The remainder of the peer-reviewed funding portfolio includes grants focused on cellular cancer mechanisms from the National Institutes of Health, the Department of Defense, Susan G. Komen Foundation, and the American Cancer Society. Ninety-three percent of full members have current, peer- reviewed, cancer-focused funding. In the current funding cycle, CRR members published 266 cancer-focused papers; 14% of these represent intra-programmatic collaborations, and 41% stem from inter-programmatic collaborations. The synergistic aims of the CRR Program create a highly productive, collaborative, and impactful research environment that is bolstered by the organizational capacity, infrastructure, and Shared Resources of the Cancer Center. CRR fosters excellence in basic science discovery in cancer biology; 28% of this Program’s papers were high-impact publications (journal impact factor >10). These discoveries directly led to six new investigator-initiated trials in the current funding period. Program Leaders facilitate meaningful, productive, interdisciplinary collaborations to achieve the goal of discovering and exploiting new mechanisms that underlie tumorigenesis and metastasis. Our success in collaborative intra- and inter-programmatic science is underscored by successful competition for nine new multi-principal investigator grants in the current funding period.

细胞反应和调节 摘要 细胞反应和调节（CRR）项目是亨斯迈癌症研究所的一个基础科学项目 （HCI）。CRR发现科学支持中心的使命“从一开始就了解癌症”， 获得对癌症生物学基本机制的新见解，并为解决关键问题提供基础。 根据HCI的战略计划解决临床问题。CRR成员利用科学的独创性和广泛的 HCI提供的共享资源来进行新的发现，他们与 癌症控制和人口科学计划和实验治疗计划翻译 这些发现在癌症预防、靶点识别、生物标志物 发展、诊断学、诊断学和治疗发展。CRR研究主要集中在以下方面 具体目的：1）阐明细胞增殖、分化和存活的机制; 2） 揭示介导肿瘤转移的机制和途径; 3）了解肿瘤的发展， 对治疗反应。 委员会由三十七名成员组成，分别代表香港中文大学的十五个学系及四所学校/学院。 犹他州大学。CRR成员资金充足，拥有820万美元的同行评审赠款资金，其中300万美元 (33%）来自NCI。同行评审的资金组合的其余部分包括专注于移动通信的赠款。 美国国家卫生研究院，国防部，苏珊G。科门 基金会和美国癌症协会。93%的正式成员有当前的，同行的- 经过审查的、以癌症为重点的资金。在当前的资助周期中，CRR成员发布了266份以癌症为重点的 论文;其中14%代表计划内合作，41%来自计划间合作 合作。 CRR计划的协同目标创造了一个高效，协作和有影响力的研究 由组织能力、基础设施和共享资源支持的环境 癌症中心CRR促进癌症生物学基础科学发现的卓越;该计划的28% 论文是高影响力出版物（期刊影响因子>10）。这些发现直接导致了六个新的 在当前资助期内，由制药商发起的试验。项目领导者促进有意义的，富有成效的， 跨学科合作，以实现发现和利用新机制的目标， 肿瘤发生和转移。我们在合作内部和跨计划科学的成功是 在目前的资金中，9名新的多名主要研究者赠款的成功竞争突出了这一点 期